ctDNA and utDNA biomarkers predict response in bladder cancer скачать в хорошем качестве

ctDNA and utDNA biomarkers predict response in bladder cancer

Jonathan Anker, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the role of cell-free DNA, including circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA), in predicting treatment outcomes in bladder cancer. Patients with undetectable ctDNA at baseline or on-treatment are more likely to achieve a clinical complete response, and ctDNA status may inform the need for escalated therapy or have implications for the curative potential of definitive local therapy. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.